低剂量亲溶解调解剂暂时重置了对微生物炎症的溶解反应
Charles N Serhan1, Nan Chiang2, Robert Nshimiyimana2
1Department of Anesthesiology, Perioperative and Pain Medicine, Center for Experimental Therapeutics and Reperfusion Injury, Mass General Brigham and Harvard Medical School, 60 Fenwood Rd., Hale Building for Transformative Medicine 3-016, Boston, MA, 02115, USA. cserhan@bwh.harvard.edu.
Molecular medicine (Cambridge, Mass.)
|September 18, 2024
概括
在正在进行的炎症期间感染会破坏自然解决过程. 低剂量专门的亲解决媒介 (SPMs) 可以重新编程这些反应,加速愈合和免疫恢复.
科学领域:
- 免疫学 免疫学 免疫学
- 炎症解决方法 生物学
背景情况:
- 专门的亲解决媒介 (SPMs) 对于解决炎症,清除感染和促进组织再生至关重要.
- 在急性炎症期间,SPM调节内源性解脱反应以恢复平衡.
- 这项研究调查了感染如何影响解决方案,以及重复的SPM管理是否可以重新编程这些反应.
研究的目的:
- 为了确定正在进行的炎症期间发起的感染是否会改变内源性解决方案.
- 调查低剂量,重复的SPM疗法对解决反应的重编程的潜力.
主要方法:
- 使用齐莫桑,然后是大肠杆菌感染的小鼠腹膜炎模型.
- 通过流细胞计和质谱计对排泄白细胞,脂质媒介和SPM配置文件进行分析.
- 进行一次重复的低剂量SPM面板 (RvD1,RvD2,RvD5,MaR1,RvE2) 接着进行齐莫桑挑战.
- 通过RNA测序评估白细胞组成,分辨率指数和基因表达.
主要成果:
- 大肠杆菌感染启动了临时性SPM的产生,但之前的齐莫桑诱导的炎症延迟了病原体的清除和改变了分辨率指数.
- 在传染性炎症和解消阶段,代谢脂组学揭示了明显的SPM集群 (RvD1,RvD5,MaR1).
- 在一个由齐莫桑诱导的炎症模型中,重复的低剂量SPM给药加速了PMN清除,并将分辨率间隔缩短了70%以上.
- RNA测序表明,低剂量的SPM调节了参与免疫反应,化学激素清除和组织修复的基因和途径.
结论:
- 在持续炎症期间发生的感染可以通过特定的SPM集群重置炎症解决机制.
- 低剂量的SPM管理可以有效地重编程先天免疫反应和途径,促进解决.
- 这些发现凸显了SPM在治疗复杂炎症状况方面的治疗潜力.
相关概念视频
01:28Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
01:38Inflammation
53.2K
Overview
53.2K
01:24Inflammatory Response II: Inflammatory Exudate and Tissue Repair
4.8K
The immune system's inflammatory response destroys the invading pathogen, permitting the tissue to heal. The changes during the cellular and vascular stages allow exudate formation at the site of inflammation. The inflammatory exudate released from the wound has high protein content and a specific gravity above 1.020.
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
4.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
360
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
360
01:24T Cell Types and Functions
960
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
960
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119